Identifying high-risk combinations of metformin during COVID-19
Some combinations of metformin with second-line antidiabetic drugs might require caution in the context of chronic diabetes mellitus type 2 therapy and COVID-19 related deaths. Findings should be interpreted as hypothesis-generating signals from real-world data rather than evidence of causal drug effects. Further research is needed, especially for metformin+GLP-1 agonist, as well as head-to-head comparisons of combinations therapies.
Authors
- Ognjen Brborović (ORCID: https://orcid.org/0000-0002-4852-2495)
- Tamara Buble (ORCID: https://orcid.org/0000-0003-1356-4166)
- Hana Brborović (ORCID: https://orcid.org/0000-0003-0844-0054)
- Tamara Poljičanin
- Jelena Dimnjaković
- Emanuel Brađašević (ORCID: https://orcid.org/0000-0001-9398-7403)
Institutions
- University of Zagreb (HR)
- Hrvatski zavod za javno zdravstvo (HR)
- University of Applied Health Sciences (HR)
- Institute for Medical Informatics and Biostatistics (CH)
Publication Details
- Journal
- PLoS ONE
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1371/journal.pone.0343979
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00